People: Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.27USD
24 Jul 2014
Price Change (% chg)

$-0.00 (-0.74%)
Prev Close
$0.27
Open
$0.27
Day's High
$0.28
Day's Low
$0.26
Volume
355,702
Avg. Vol
936,584
52-wk High
$0.55
52-wk Low
$0.19

Search Stocks

Summary

Name Age Since Current Position

William Carter

75 2006 Chairman of the Board, Chief Executive Officer, Chief Scientific Officer

Thomas Equels

61 2013 Executive Vice Chairman of the Board, Chief Financial Officer, General Counsel, Secretary, Litigation Counsel

Wayne Springate

42 2011 Senior Vice President - Operations

Adam Pascale

2013 Chief Accounting Officer

Ralph Cavalli

55 2010 Vice President - Quality Control

David Strayer

67 2010 Chief Medical Officer, Medical Director - Regulatory Affairs

Iraj Kiani

67 2013 Lead Independent Director

Peter Rodino

61 2013 Director

William Mitchell

78 1998 Independent Director

Charles Jones

2012 Associates Public Relations

Biographies

Name Description

William Carter

Dr. William A. Carter, M.D., is Chairman of the Board, Chief Executive Officer, Chief Scientific Officer of Hemispherx Biopharma Inc. He the co-inventor of Ampligen®, joined us in 1978, and has served as: (a) our Chief Scientific Officer since May 1989; (b) the Chairman of our Board of Directors since January 1992; (c) our Chief Executive Officer since July 1993; (d) our President from April 1995 to November 2006 and then again December 2011 to present; and (e) a Director since 1987. From 1987 to 1988, Dr. Carter served as our Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. Dr. Carter received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. From 1985 to October 1988, Dr. Carter served as our Chief Executive Officer and Chief Scientist. He received his M.D. degree from Duke University and underwent his post-doctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahnemann Medical University, a position he held from 1980 to 1998. Dr. Carter served as Professor and Director of Clinical Research for Hahnemann Medical University's Institute for Cancer and Blood Diseases, and as a member of the faculty at Johns Hopkins School of Medicine and the State University of New York at Buffalo. Dr. Carter is a Board certified physician and author of more than 200 scientific articles, including the editing of various textbooks on anti-viral and immune therapy.

Thomas Equels

Mr. Thomas K. Equels is Executive Vice Chairman of the Board, Chief Financial Officer, General Counsel, Secretary, Litigation Counsel of Hemispherx Biopharma Inc. Mr. Equels' experience and education provide a firm basis for his service as Chief Financial Officer. For more than thirty years his legal practice focused on complex business litigation, including cases related to corporate finance and market issues. Mr. Equels is the President and Managing Director of the Equels Law Firm based in Miami Florida that focuses on litigation. For over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree from Troy. He is a member of the Florida Bar Association and the American Bar Association.

Wayne Springate

Mr. Wayne S. Springate is Senior Vice President - Operations of Hemispherx Biopharma Inc. He was promoted to Senior Vice President of Operations on May 1, 2011. Mr. Springate came on board when Hemispherx acquired Alferon N Injection® and its New Brunswick, NJ manufacturing facility. He led the consolidation of our Rockville facility to our New Brunswick location as well as coordinated the relocation of manufacturing polymers from South Africa to our production facility in New Brunswick. He was also responsible for preparing and having a successful Preapproval Inspection by the FDA for our New Brunswick manufacturing plant in connection with the filing of our Ampligen® NDA. Currently he is managing a capital improvement budget to enhance our Alferon® facility in accordance with current Good Manufacturing Practice (“cGMP”). Previously, Mr. Springate served as President for World Fashion Concepts in New York and oversaw operations at several locations throughout the United States and overseas. Mr. Springate assists the CEO in details of operations on a daily basis and is involved in all aspects of manufacturing, warehouse management, distribution and logistics.

Adam Pascale

Mr. Adam Pascale is Chief Accounting Officer of the company. Mr. Pascale has been the Controller at Hemispherx for eighteen years, with twenty four years of public accounting experience and prior public company experience. His degree is from Rutgers University in Accounting and he served for many years as a CPA prior to joining Hemispherx. He is a member of both the American and the Pennsylvania Institutes of Certified Public Accountants. According to Mr. Equels, "Adam has the education and experience to excel in the function of Chief Accounting Officer. I look forward to working with him to create a stronger, better, Hemispherx."

Ralph Cavalli

Dr. Ralph Christopher Cavalli, Ph.D., is Vice President - Quality Control of Hemispherx Biopharma Inc., since April 15, 2010. Dr. Cavalli most recently served as Director of Quality Control at the Company’s New Brunswick, NJ manufacturing facility. He is currently responsible for manufacturing Alferon® Purified Drug Concentrate and active pharmaceutical ingredients for Ampligen® along with overseeing our Quality Control (“QC”) Department to continue our Good Laboratory Practices and Good Manufacturing Practices. Prior to joining Hemispherx, Dr. Cavalli served as Senior Director of Manufacturing Operations at Cytogen Corporation from 2006 until 2009, where he was responsible for the manufacture of Cytogen’s three commercial products. From 1999 until 2006, he initially worked at Discovery Laboratories as Associate Director of Analytical Services and then ultimately as Senior Director of Analytical and Technical Services, for which he was responsible for Quality Control and Process Development. Dr Cavalli received a Ph.D. in Chemistry from Temple University in Philadelphia, PA.

David Strayer

Dr. David R. Strayer, M.D., is Chief Medical Officer, Medical Director - Regulatory Affairs of Hemispherx Biopharma Inc.He has served as Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University from 1987 to 1998. Dr. Strayer is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. He has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972.

Iraj Kiani

Dr. Iraj Eqhbal Kiani, N.D., Ph.D., is Lead Independent Director of Hemispherx Biopharma Inc. Dr. Kiani is a citizen of the United States and England and resides in Newport Beach, California. Dr. Kiani served in various local government positions including the Mayor and Governor of Yasoug, Capital of Boyerahmand, Iran. In early 1980, Dr. Kiani moved to England, where he established and managed several trading companies over a period of some 20 years. Dr. Kiani is a planning and logistic specialist who is now applying his knowledge and experience to build a worldwide immunology network, which will use our proprietary technology. Dr. Kiani received his Ph.D. degree from the University of Ferdosi in Iran, and his ND from American University.

Peter Rodino

Mr. Peter W. Rodino III, Esq., is Director of Hemispherx Biopharma, Inc. Mr Rodino has been the President and Managing director of Rodino Consulting, which specializes in guiding small and mid-sized companies through successive stages of developing business plans and implementing marketing strategies. He has acted as managing partner at the law firms Rodino Forman and D'Uva from 1980-1990 and Rodino and Rodino from 1990-1999 in Essex County New Jersey. During his many years as a practicing attorney, he has represented numerous fortune 100 companies and has acted as Trustee in numerous Chapter 11 complex corporate re-organizations. Mr. Rodino attained his broad financial and executive experience when in 1992 he served as Chairman and Chief Executive Officer of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. From 1996 through 1999 he served as an investment executive in the securities industry for Ryan Beck in West Orange, New Jersey. Mr Rodino is a graduate of Georgetown University with a Bachelors Degree in Business and earned his Juris Doctor Degree in 1976 from Seton Hall Law School. He is a retired member of the New Jersey and New York Bar Associations.

William Mitchell

Dr. William M. Mitchell, M.D., Ph.D., is Independent Director of Hemispherx Biopharma Inc., since July 1998. Dr. Mitchell is a Professor of Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine and is a board certified physician. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as House Officer in Internal Medicine, followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to viruses, anti-viral drugs, immune responses to HIV infection, and other biomedical topics. Dr. Mitchell has worked for and with many professional societies that have included the American Society of Investigative Pathology, the International Society for Antiviral Research, the American Society of Biochemistry and Molecular Biology and the American Society of Microbiology. Dr. Mitchell is a member of the American Medical Association. He has served on numerous government review committees, among them the National Institutes of Health, AIDS and Related Research Review Group. Dr. Mitchell previously served as one of our Directors from 1987 to 1989.

Charles Jones

Basic Compensation

Name Fiscal Year Total

William Carter

1,465,960

Thomas Equels

915,608

Wayne Springate

344,164

Adam Pascale

--

Ralph Cavalli

244,002

David Strayer

291,095

Iraj Kiani

--

Peter Rodino

--

William Mitchell

--

Charles Jones

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

William Carter

5,773,919 359,794

Thomas Equels

0 0

Wayne Springate

0 0

Adam Pascale

0 0

Ralph Cavalli

0 0

David Strayer

150,000 11,200

Iraj Kiani

0 0

Peter Rodino

0 0

William Mitchell

0 0

Charles Jones

0 0
Search Stocks